Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

Y0000439

Didanosine

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

2′,3′-Dideoxyinosine, ddI, ddIno

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C10H12N4O3
Número de CAS:
69655-05-6
Peso molecular:
236.23
Beilstein:
3619529
Número MDL:
MFCD00077728
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329830956
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

didanosine

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

OC[C@@H]1CC[C@@H](O1)n2cnc3C(=O)NC=Nc23

InChI

1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1

Clave InChI

BXZVVICBKDXVGW-NKWVEPMBSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Didanosine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0000440

Didanosine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0000442

Didanosine impurity G, European Pharmacopoeia (EP) Reference Standard

Y0000441

Didanosine impurity A,, European Pharmacopoeia (EP) Reference Standard

1191204

Didanosine, United States Pharmacopeia (USP) Reference Standard

1191237

Didanosine Related Compound B, United States Pharmacopeia (USP) Reference Standard

1191215

Didanosine System Suitability Mixture, United States Pharmacopeia (USP) Reference Standard

1191226

Didanosine Related Compound A, United States Pharmacopeia (USP) Reference Standard

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Tenofovir and didanosine: a dangerous liaison.
Laura Waters et al.
The AIDS reader, 15(8), 403-406 (2005-08-23)
Rosario Palacios et al.
Expert review of anti-infective therapy, 4(6), 965-971 (2006-12-22)
There are currently several suitable and different antiretroviral regimens to start highly active antiretroviral therapy (HAART), and many clinicians and patients prefer once-daily therapy. The efficacy and potency of efavirenz (EFV) has been established in many clinical trials and cohort
Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review.
Géraldine D'Ythurbide et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 22(12), 3656-3659 (2007-10-02)
Marco Bongiovanni et al.
Current medicinal chemistry, 13(23), 2789-2793 (2006-11-01)
Nucleoside reverse transcriptase inhibitors (NRTI) are essential components of highly active antiretroviral treatment (HAART). Although several combinations can be used as NRTI backbones, not all are associated with good virological and/or immunological results. In particular, some NRTI combinations should be
J J McGowan et al.
Reviews of infectious diseases, 12 Suppl 5, S513-S520 (1990-07-01)
AIDS has remained a significant and worsening medical problem since its first description as a new clinical entity in 1981. In the past 6 years, substantial progress has been made in the chemotherapy for this disease; such progress is likely
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico